Clinical significance of initial treatment for peritoneal lavage cytology-positive gastric cancer: outcomes according to treatment strategy

Table 5 Clinicopathological features of 3-year survivors

Case	Category	Age	Sex	p-Depth of invasion	p-lymph node metastasis	Histology	Tumor diameter (mm)	Regimens of chemotherapy	Survival time (months)	Status
1	Gastrectomy with adjuvant chemotherapy	56	M	SE	N1	tub2	45	S-1, SP	81.2	Alive
2	Gastrectomy with adjuvant chemotherapy	32	M	SE	N3	sig	80	S-1	58.8	Dead
3	Gastrectomy with adjuvant chemotherapy	61	M	SE	N1	por	40	SOX, S-1	46.4	Alive
4	Gastrectomy with adjuvant chemotherapy	61	M	SE	N2	por	50	S-1	40.2	Alive
5	Conversion gastrectomy	57	F	SS	N0	por	133	SP	68.9	Dead
6	Conversion gastrectomy	74	M	SS	N0	tub1	25	SP	57.4	Alive
7	Palliative chemotherapy	67	F	cSE	NX	por	80	XELOX	39.6	Alive

tub1 well-differentiated tubular adenocarcinoma, tub2 moderately differentiated tubular adenocarcinoma, por poorly differentiated adenocarcinoma, sig signet ring cell carcinoma, SOX S-1 plus oxaliplatin, SP S-1 plus cisplatin, XELOX capecitabine plus oxaliplatin

ISSN: 1477-7819